The Indian Journal of Pediatrics

, Volume 70, Issue 6, pp 485–488 | Cite as

Pertussis vaccine controversies and acellular pertussis vaccine

  • Raju C. ShahEmail author
  • Anuj R. Shah
Symposium on Controversies in Immunization-I


Pertussis still continues to cause significant morbidity and mortality worldwide. Because of the high reactogenicity of whole cell pertussis vaccine, it had evoked public controversy in several countries. In 1970 Japan abandoned use of whole cell pertussis vaccine and mounted efforts to develop better vaccine. To date, nearly 24 acellular pertussis vaccines have been developed, using different number and quantity of components. No acellular vaccine is most or least immunogenic with respect to all included antigens. Vaccine efficacy and duration of immunity is comparable with whole cell pertussis vaccine. The adverse events are two thirds less compared to whole cell vaccine.

Key words

Components of B. Pertussis Neurological events Immunogenicity Efficacy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Centers for Disease Control and Prevention: Pertussis vaccinations: Use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Morb Mortal wkly Rep 1997; 46: (RR-7): 1–25.Google Scholar
  2. 2.
    Centers for disease and prevention: Recommended Childhood Immunization Schedule – United States, 1999. MMWRMorb Mortal Wkly Rep 1999; 48: 12.Google Scholar
  3. 3.
    Cherry JD, Mortimer EA Jr. Hackell JGet al and the Multicenter vaccine study groups: Clinical trials in the United States and Japan with the Lederle–Takeda and Takeda acellular pertussis–diphtheria-tetanus (APDT) vaccines.Dev Biol Stand 1991; 73: 51.PubMedGoogle Scholar
  4. 4.
    Decker MD, Edwards KM; Steinhoff MCet al. Comparison of 13 acellular pertussis vaccines. Adverse reactions.Pediatrics 1995; 96: 557.PubMedGoogle Scholar
  5. 5.
    Edwards KM, Meade BD, Decker MDet al. Comparison of 13 acellular pertussis vaccines: Overview and serologic response.Pediatrics 1995; 96: 548.PubMedGoogle Scholar
  6. 6.
    Global programme on vaccines: State of the World’s Vaccines and Immunization, Geneva World Health Organization and UNICEF 1996.Google Scholar
  7. 7.
    Kimura M, Kuno-Sakai H. Developments in pertussis immunisation in Japan.Lancet 1990; 336: 30.PubMedCrossRefGoogle Scholar
  8. 8.
    Morgan CM, Blumberg DA, Cherry JDet al. Comparison of acellular and whole cell pertussis component DTP vaccines: A Multicenter double-blind study in 4 to 6-year-old children.Am J Dis Child 1990; 144: 41.PubMedGoogle Scholar
  9. 9.
    Olin P, Gustaffson Let al. For the ad hoc Group for the study of pertussis vaccines: Randomised controlled trial of two component, three component, and five component acellular pertussis vaccines compared with whole cell pertussis vaccine.Lancet 1997; 350: 1569.PubMedCrossRefGoogle Scholar
  10. 10.
    Pichichero ME, Deloria, MA, Rennels MBet al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole cell pertussis vaccine given as a son of 12 acellular pertussis vaccines and one whole cell pertussis vaccine given as a fourth dose in 15 to 20-month old children.Pediatrics 1997; 100: 772.PubMedCrossRefGoogle Scholar
  11. 11.
    Pichichero ME, Edwards KM, Andersonet al. Safety and immunogenicity of six acellular pertussis vaccines and one whole cell pertussis vaccine given as a fifth dose in four to six-year-old children.Pediatrics 2000; 105.Google Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2003

Authors and Affiliations

  1. 1.S.C.L. Municipal Hospital and Smt. N.H.L. Municipal Medical CollegeAhmedabadIndia

Personalised recommendations